| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4003200 | American Journal of Ophthalmology | 2011 | 10 Pages |
Abstract
In 2008, bevacizumab was used at a higher rate than ranibizumab for the treatment of neovascular AMD. Even though bevacizumab accounted for 58% of all injections, Medicare paid $516 million more for ranibizumab than bevacizumab. These data suggest that despite its off-label designation, intravitreal bevacizumab is currently the standard-of-care treatment for neovascular AMD in the United States.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Ross J. Brechner, Philip J. Rosenfeld, J. Daniel Babish, Stuart Caplan,